Aurelia L, Purcell R, Theisen R, Kelly A, Esterbauer R, Ramanathan P
Sci Adv. 2025; 11(9):eads1482.
PMID: 40009690
PMC: 11864192.
DOI: 10.1126/sciadv.ads1482.
Ogulur I, Mitamura Y, Yazici D, Pat Y, Ardicli S, Li M
Cell Mol Immunol. 2025; 22(3):211-242.
PMID: 39962262
PMC: 11868591.
DOI: 10.1038/s41423-025-01261-2.
Lim J, Jensen S, Plomp J, Vankerckhoven B, Kneip C, Coppejans R
iScience. 2025; 28(2):111684.
PMID: 39898046
PMC: 11783450.
DOI: 10.1016/j.isci.2024.111684.
Pandey J, Nietert P, Namboodiri A, Kimball C, Flume P
Genes Immun. 2025; .
PMID: 39774260
DOI: 10.1038/s41435-024-00318-y.
Huhn A, Nissley D, Wilson D, Kutuzov M, Donat R, Tan T
Nat Commun. 2025; 16(1):338.
PMID: 39746910
PMC: 11695720.
DOI: 10.1038/s41467-024-54916-5.
Detection of antibodies to infliximab in routine care: a 4-year French retrospective study.
Bertin D, Aghzadi J, Balandraud N, Roman C, Serrero M, Desplat-Jego S
Clin Exp Immunol. 2024; 219(1).
PMID: 39714327
PMC: 11747995.
DOI: 10.1093/cei/uxae122.
Advances in B Cell Targeting for Treating Muscle-Specific Tyrosine Kinase-Associated Myasthenia Gravis.
Hu G, Zhao X, Wang Y, Zhu X, Sun Z, Yu X
Immunotargets Ther. 2024; 13:707-720.
PMID: 39678139
PMC: 11646387.
DOI: 10.2147/ITT.S492062.
Facilitating high throughput bispecific antibody production and potential applications within biopharmaceutical discovery workflows.
Fawcett C, Tickle J, Coles C
MAbs. 2024; 16(1):2311992.
PMID: 39674918
PMC: 10883111.
DOI: 10.1080/19420862.2024.2311992.
Discovery and Characterization of Unusual O-Linked Glycosylation of IgG4 Antibody Using LC-MS.
Janecki D, Kao-Scharf C, Hoffmann A
Rapid Commun Mass Spectrom. 2024; 39(5):e9969.
PMID: 39663547
PMC: 11635057.
DOI: 10.1002/rcm.9969.
Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab.
Selmaj K, Roth K, Hofler J, Vitzithum K, Derlacz R, von Richter O
BioDrugs. 2024; 38(6):755-767.
PMID: 39343860
PMC: 11530514.
DOI: 10.1007/s40259-024-00671-4.
A PD-1-targeted, receptor-masked IL-2 immunocytokine that engages IL-2Rα strengthens T cell-mediated anti-tumor therapies.
Wu J, Bloch N, Chang A, Bhavsar R, Wang Q, Crawford A
Cell Rep Med. 2024; 5(10):101747.
PMID: 39326410
PMC: 11513833.
DOI: 10.1016/j.xcrm.2024.101747.
IgG4 glycosylation contributes to the pathogenesis of IgG4 Hashimoto's thyroiditis via the complement pathway.
Zhao C, Sun Z, Wang S, Zhang J, Liu J, Chen L
Eur Thyroid J. 2024; 13(5).
PMID: 39316722
PMC: 11558973.
DOI: 10.1530/ETJ-24-0156.
IgE versus IgG and IgA: Differential roles of allergen-specific antibodies in sensitization, tolerization, and treatment of allergies.
Knol E, van Neerven R
Immunol Rev. 2024; 328(1):314-333.
PMID: 39285523
PMC: 11659938.
DOI: 10.1111/imr.13386.
Repeated COVID-19 mRNA vaccination results in IgG4 class switching and decreased NK cell activation by S1-specific antibodies in older adults.
Gelderloos A, Verheul M, Middelhof I, de Zeeuw-Brouwer M, Van Binnendijk R, Buisman A
Immun Ageing. 2024; 21(1):63.
PMID: 39272189
PMC: 11401348.
DOI: 10.1186/s12979-024-00466-9.
Fc-Fc interactions and immune inhibitory effects of IgG4: implications for anti-PD-1 immunotherapies.
Zhang W, Chen X, Chen X, Li J, Wang H, Yan X
J Immunother Cancer. 2024; 12(6).
PMID: 38925680
PMC: 11203076.
DOI: 10.1136/jitc-2024-009034.
Advancements and prospects of novel biologicals for myasthenia gravis: toward personalized treatment based on autoantibody specificities.
Ma C, Liu D, Wang B, Yang Y, Zhu R
Front Pharmacol. 2024; 15:1370411.
PMID: 38881870
PMC: 11177092.
DOI: 10.3389/fphar.2024.1370411.
IgG4-related disease-rare but you should not forget it.
Pinheiro F, Pereira I, de Souza A, Mayrink Giardini H, Cordeiro R
Adv Rheumatol. 2024; 64(1):35.
PMID: 38702764
DOI: 10.1186/s42358-024-00374-y.
Exploring the depths of IgG4: insights into autoimmunity and novel treatments.
Unlu S, Sanchez Navarro B, Cakan E, Berchtold D, Meleka Hanna R, Vural S
Front Immunol. 2024; 15:1346671.
PMID: 38698867
PMC: 11063302.
DOI: 10.3389/fimmu.2024.1346671.
Current and future advances in practice: IgG4-related disease.
Wallace Z, Katz G, Hernandez-Barco Y, Baker M
Rheumatol Adv Pract. 2024; 8(2):rkae020.
PMID: 38601138
PMC: 11003820.
DOI: 10.1093/rap/rkae020.
Impact of the SARS-CoV-2 Spike Protein on the Innate Immune System: A Review.
Bocquet-Garcon A
Cureus. 2024; 16(3):e57008.
PMID: 38549864
PMC: 10973921.
DOI: 10.7759/cureus.57008.